DE69839273D1 - Krebs immuntherapie mit semi-allogenen zellen - Google Patents

Krebs immuntherapie mit semi-allogenen zellen

Info

Publication number
DE69839273D1
DE69839273D1 DE69839273T DE69839273T DE69839273D1 DE 69839273 D1 DE69839273 D1 DE 69839273D1 DE 69839273 T DE69839273 T DE 69839273T DE 69839273 T DE69839273 T DE 69839273T DE 69839273 D1 DE69839273 D1 DE 69839273D1
Authority
DE
Germany
Prior art keywords
semi
cells
cancer immunotherapy
allogeneic
allogenic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839273T
Other languages
English (en)
Other versions
DE69839273T2 (de
Inventor
Edward P Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69839273D1 publication Critical patent/DE69839273D1/de
Publication of DE69839273T2 publication Critical patent/DE69839273T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69839273T 1997-01-31 1998-01-30 Krebsimmuntherapie mit semi-allogenen zellen Expired - Lifetime DE69839273T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3662097P 1997-01-31 1997-01-31
US36620P 1997-01-31
PCT/US1998/001824 WO1998033527A2 (en) 1997-01-31 1998-01-30 Cancer immunotherapy with semi-allogeneic cells

Publications (2)

Publication Number Publication Date
DE69839273D1 true DE69839273D1 (de) 2008-04-30
DE69839273T2 DE69839273T2 (de) 2009-03-05

Family

ID=21889646

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839273T Expired - Lifetime DE69839273T2 (de) 1997-01-31 1998-01-30 Krebsimmuntherapie mit semi-allogenen zellen

Country Status (7)

Country Link
US (3) US6187307B1 (de)
EP (1) EP1012240B1 (de)
JP (1) JP2001522226A (de)
AT (1) ATE389712T1 (de)
CA (1) CA2278678A1 (de)
DE (1) DE69839273T2 (de)
WO (1) WO1998033527A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012240B1 (de) * 1997-01-31 2008-03-19 Edward P. Cohen Krebs immuntherapie mit semi-allogenen zellen
US6503503B1 (en) * 1997-05-13 2003-01-07 Duke University Allogeneic cellular vaccine
WO2000076537A2 (en) * 1997-09-10 2000-12-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases
EP1272224A4 (de) * 2000-03-31 2004-09-29 Gene Logic Inc Genexpressionsprofile im gewebe der speiseröhre
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
DE10112851C1 (de) * 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US7955845B2 (en) * 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
WO2003103707A1 (en) * 2002-06-06 2003-12-18 Immunicum Ab New method and composition for producing a cellular allogeneic vaccine
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
ES2676503T3 (es) * 2002-12-16 2018-07-20 Globeimmune, Inc. Vacunas basadas en levadura como inmunoterapia
WO2004064785A2 (en) 2003-01-14 2004-08-05 Dana Farber Cancer Institute Cancer therapy sensitizer
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
EP2460533A3 (de) 2004-10-18 2014-01-08 Globeimmune, Inc. Therapeutikum auf Hefebasis gegen chronische Hepatitis-C-Infection
WO2006112930A2 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
CA2603191A1 (en) * 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
EP2268306A2 (de) * 2008-03-14 2011-01-05 The Board Of Trustees Of The University Of Illinois Therapeutische krebsantigene
JP2011516609A (ja) * 2008-04-14 2011-05-26 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Ｓｐａｒｃ抗炎症活性及びその使用
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
WO2010058023A1 (en) 2008-11-24 2010-05-27 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh High affinity t cell receptor and use thereof
US9763982B2 (en) 2010-06-29 2017-09-19 The Regents Of The University Of California Depletion of cancer stem cells
US20120009203A1 (en) * 2010-06-29 2012-01-12 Anahid Jewett Depletion of cancer stem cells
JP2018090491A (ja) * 2015-04-01 2018-06-14 株式会社細胞治療技術研究所 癌ワクチンの製造方法、及び癌ワクチン
CN117838729A (zh) 2017-04-13 2024-04-09 森迪生物科学公司 组合癌症免疫疗法
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
KR20210094534A (ko) 2018-10-17 2021-07-29 센티 바이오사이언시스, 인코포레이티드 병용 암 면역 요법
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674486A (en) 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
JP3524918B2 (ja) 1991-10-25 2004-05-10 サン ディエゴ リージョナル キャンサー センター 癌のリンホカイン遺伝子療法
IL105008A0 (en) 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
EP0569678A3 (de) 1992-03-13 1994-10-26 Yeda Res & Dev Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen.
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer
US6022538A (en) 1995-06-06 2000-02-08 The Wistar Institute Of Anatomy And Biology Method of treating malignancies
UY24367A1 (es) * 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
US6805869B2 (en) 1996-06-12 2004-10-19 Shanghai Cp Guojian Pharmaceutical Co., Ltd. Cellular vaccines and immunotherapeutics and methods for their preparation
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US6063375A (en) 1996-09-10 2000-05-16 Medical University Of South Carolina Semiallogeneic cell hybrids and related methods for treating cancer
GB9620350D0 (en) 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
EP1012240B1 (de) * 1997-01-31 2008-03-19 Edward P. Cohen Krebs immuntherapie mit semi-allogenen zellen
DE60128070T2 (de) 2000-02-14 2008-01-10 The Regents Of The University Of California, Oakland Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
CA2603191A1 (en) 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods

Also Published As

Publication number Publication date
US7670611B2 (en) 2010-03-02
US6187307B1 (en) 2001-02-13
JP2001522226A (ja) 2001-11-13
DE69839273T2 (de) 2009-03-05
EP1012240B1 (de) 2008-03-19
EP1012240A2 (de) 2000-06-28
US7402306B1 (en) 2008-07-22
ATE389712T1 (de) 2008-04-15
US20080305131A1 (en) 2008-12-11
WO1998033527A2 (en) 1998-08-06
CA2278678A1 (en) 1998-08-06
WO1998033527A3 (en) 1998-11-05

Similar Documents

Publication Publication Date Title
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
Shimizu et al. Enhancement of tumor lysate-and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein
Davis An overview of cancer immunotherapy
EP0789574A4 (de) Verfahren und vorrichtungen zur immunisierung eines wirts gegen tumorassoziierte antigene durch verabreichung nackter polynukleotide, die für tumorassoziierte antigene peptide kodieren
TR200100936T2 (tr) Terapötik aşılama
Pampena et al. Natural killer cells as helper cells in dendritic cell cancer vaccines
CA2267157A1 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
ZA91559B (en) Vaccines against cancer and infectious diseases
Ma et al. Anti‐tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution
NO986173L (no) FremgangsmÕte for aktivering av dendrittceller
Lewis Therapeutic cancer vaccines: using unique antigens
CY1106400T1 (el) Συνθεση και μεθοδος ανοσοθepαπειας με καρκινικο αντιγονο
Geary et al. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN
LV12085A (lv) Dendritiskas sunas stimulejosais faktors
Prins et al. Immunology and immunotherapy in neurosurgical disease
Assudani et al. In vivo Expansion, Persistence, and Function of Peptide Vaccine–Induced CD8 T Cells Occur Independently of CD4 T Cells
ZA200401842B (en) Process for the maturation of dentritic cells and a vaccine.
Wang et al. Prime–boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice
WO2006062917A2 (en) Alpha thymosin peptides as cancer vaccine adjuvants
Santin et al. Effects of irradiation on the expression of surface antigens in human ovarian cancer
PT1171587E (pt) Peptido derivado do antigenio muc-1 para desencadear uma reaccao imunitaria contra celulas tumorais
Conforti et al. Update on active specific immunotherapy with melanoma vaccines
Dezfouli et al. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNγ primed and IFNβ treated B7‐1+ B16‐F10 melanoma cells
DE60130634D1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
Sato Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition